canertinib has been researched along with terazosin in 1 studies
| Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (terazosin) | Trials (terazosin) | Recent Studies (post-2010) (terazosin) |
|---|---|---|---|---|---|
| 124 | 9 | 65 | 658 | 173 | 104 |
| Protein | Taxonomy | canertinib (IC50) | terazosin (IC50) |
|---|---|---|---|
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.428 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 6.042 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.011 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.005 | |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | 0.005 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bansal, R; Malhotra, A | 1 |
1 review(s) available for canertinib and terazosin
| Article | Year |
|---|---|
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Quinazolines | 2021 |